• Save $90 until Aug 21: Register Now for Early Bird Savings!
    38th Annual GAPNA Conference

    October 3-5, 2019 at the Paris Hotel, Las Vegas, NV.

    Focused education; lasting connections, networking, free access to the GAPNA Online Library.

    Earn up to 22 contact hours (including pre-conference workshops).

    Get more information and register now!

  • 2019 Senior Report Senior Report: Older Americans have more options for home care, but still struggling.

    The United Health Foundation has released results of a sweeping new study benchmarking the health of older adults. The America's Health Rankings® Senior Report was created in partnership with GAPNA to improve the health of America's seniors.

    The data will help advanced practice nurses and other providers deliver quality care.

    Find out about it!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • FREE continuing education credit is available for the following session:

    "Decisional Capacity"

    (session captured at the GAPNA 2018 Annual Conference)


    For July/August 2019 - Get Your Free CNE Now!

Current Corprate Partners

GAPNA is a name chosen to reflect the diversity of our current and potential members, all who are interested in providing the highest quality of care to older adults.

We are the only advanced practice nursing organization that focuses on older adults, the fastest growing segment of the population.

View complete details about the GAPNA Corporate Partner Program.

If you would like to discuss your involvement and more details, please contact Jack Edelman, Director of Marketing, at 856-256-2313, Jack.Edelman@ajj.com or Samantha Healy, Marketing Coordinator, at 856-256-2342, samantha.healy@ajj.com.

GAPNA thanks our current Corporate Members for their support of our organization.

  

AvanirAvanir

Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

Corporate Headquarters
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
Phone: 949-3889-6700


NeurocrineNeurocrine

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.

The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.

Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).

Corporate Headquarters
Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
Phone: 1-858-617-7600
For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)


SK Life ScienceSK Life Science

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., is focused on developing and commercializing treatments for disorders of the central nervous system (CNS). Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is located in Paramus, New Jersey.

We have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox‐Gastaux syndrome and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound for the potential treatment of partial‐onset seizures in adult patients.

For more information, visit their websites listed below.

SK Life Science
461 From Road, 5th Floor
Paramus, NJ 07652
Websites: SK life scienceSK Biopharmaceuticals.